Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome

详细信息    查看全文

• 作者：Karen Gambaro ; Michael CJ Quinn ; Katia Y Cáceres-Gorriti ; Rebecca S Shapiro…
• 关键词：IGFBP7 ; Epithelial ovarian cancer ; Gene expression ; Migration ; Tissue microarray ; Patient outcome
• 刊名：BMC Cancer
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：15
• 期：1
• 全文大小：3,111 KB
• 参考文献：Canadian Cancer Statistic 2012. Canadian Cancer Society’s Steering Commitee on Cancer Statistics, Toronto, ON
  Cancer Facts & Figures 2012. American Cancer Society, Atlanta
  1. Vaughan, S, Coward, JI, Bast, RC, Berchuck, A, Berek, JS, Brenton, JD (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11: pp. 719-25
  Physician Data Query; Ovarian Epithelial Cancer Treatment (PDQ?).
  2. Rosen, DG, Yang, G, Liu, G, Mercado-Uribe, I, Chang, B, Xiao, XS (2009) Ovarian cancer: pathology, biology, and disease models. Front Biosci 14: pp. 2089-102
  3. Lynch, HT, Casey, MJ, Snyder, CL, Bewtra, C, Lynch, JF, Butts, M (2009) Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 3: pp. 97-137
  4. Berns, EM, Bowtell, DD (2012) The changing view of high-grade serous ovarian cancer. Cancer Res 72: pp. 2701-4
  5. Ahmed, AA, Etemadmoghadam, D, Temple, J, Lynch, AG, Riad, M, Sharma, R (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221: pp. 49-56
  6. Gorringe, KL, Campbell, IG (2009) Large-scale genomic analysis of ovarian carcinomas. Mol Oncol 3: pp. 157-64
  7. Wojnarowicz, PM, Oros, KK, Quinn, MCJ, Arcand, SL, Gambaro, K, Madore, J (2012) The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome. PLoS One 7: pp. e45484
  Integrated genomic analyses of ovarian carcinoma. Nature 474: pp. 609-15
  8. Vang, R, Shih Ie, M, Kurman, RJ (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16: pp. 267-82
  9. Schwartz, DR, Kardia, SL, Shedden, KA, Kuick, R, Michailidis, G, Taylor, JM (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62: pp. 4722-9
  10. Bonome, T, Lee, JY, Park, DC, Radonovich, M, Pise-Masison, C, Brady, J (2005) Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65: pp. 10602-12
  11. Cody, NA, Ouellet, V, Manderson, EN, Quinn, MC, Filali-Mouhim, A, Tellis, P (2007) Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene 26: pp. 618-32
  12. Cody, NA, Shen, Z, Ripeau, JS, Provencher, DM, Mes-Masson, AM, Chevrette, M (2009) Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. Mol Carcinog 48: pp. 1077-92
  13. Wojnarowicz, P, Gambaro, K, Ladurantaye, M, Quinn, MC, Provencher, D, Mes-Masson, AM (2012) Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity. Oncogenesis 1: pp. e27
  14. Gambaro, K, Quinn, MC, Wojnarowicz, PM, Arcand, SL, Ladurantaye, M, Barres, V (2013) VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer. Mol Oncol 7: pp. 513-30
  15. Provencher, DM, Lounis, H, Champoux, L, Tetrault, M, Manderson, EN, Wang, JC (2000) Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 36: pp. 357-61
  16. Quinn, MC, Filali-Mouhim, A, Provencher, DM, Mes-Masson, AM, Tonin, PN (2009) Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer. Mol Carcinog 48: pp. 648-61
  17. Quinn, MC, Wojnarowicz, PM, Pickett, A, Provencher, DM, Mes-Masson, AM, Davis, EC (2013) FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome. Int J Oncol 42: pp. 912-20
  18. Burger, AM, Leyland-Jones, B, Banerjee, K, Spyropoulos, DD, Seth, AK (2005) Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer 41: pp. 1515-27
  19. Wajapeyee, N, Serra, RW, Zhu, X, Mahalingam, M, Green, MR (2008) Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132: pp. 363-74
  20. Vizioli, MG, Sensi, M, Miranda, C, Cleris, L, Formelli, F, Anania, MC (2010) IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene 29: pp. 3835-44
  21. Ruan, WJ, Lin, J, Xu, EP, Xu, FY, Ma, Y, Deng, H (2006) IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1. J Zhejiang Univ Sci B 7: pp. 929-32
  22. Chen, Y, Pacyna-Gengelbach, M, Ye, F, Knosel, T, Lund, P, Deutschmann, N (2007) Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activ
• 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2407

文摘

Background Insulin-like growth factor binding protein 7 (IGFBP7) has been suggested to act as a tumour suppressor gene in various human cancers, yet its role in epithelial ovarian cancer (EOC) has not yet been investigated. We previously observed that IGFBP7 was one of several genes found significantly upregulated in an EOC cell line model rendered non-tumourigenic as consequence of genetic manipulation. The aim of the present study was to investigate the role of IGFBP7 in high-grade serous ovarian carcinomas (HGSC), the most common type of EOC. Methods We analysed IGFBP7 gene expression in 11 normal ovarian surface epithelial cells (NOSE), 79 high-grade serous ovarian carcinomas (HGSC), and seven EOC cell lines using a custom gene expression array platform. IGFBP7 mRNA expression profiles were also extracted from publicly available databases. Protein expression was assessed by immunohistochemistry of 175 HGSC and 10 normal fallopian tube samples using tissue microarray and related to disease outcome. We used EOC cells to investigate possible mechanisms of gene inactivation and describe various in vitro growth effects of exposing EOC cell lines to human recombinant IGFBP7 protein and conditioned media. Results All HGSCs exhibited IGFBP7 expression levels that were significantly (p--.001) lower than the mean of the expression value of NOSE samples and that of a whole ovary sample. IGFBP7 gene and protein expression were lower in tumourigenic EOC cell lines relative to a non-tumourigenic EOC cell line. None of the EOC cell lines harboured a somatic mutation in IGFBP7, although loss of heterozygosity (LOH) of the IGFBP7 locus and epigenetic methylation silencing of the IGFBP7 promoter was observed in two of the cell lines exhibiting loss of gene/protein expression. In vitro functional assays revealed an alteration of the EOC cell migration capacity. Protein expression analysis of HGSC samples revealed that the large majority of tumour cores (72.6%) showed low or absence of IGFBP7 staining and revealed a significant correlation between IGFBP7 protein expression and a prolonged overall survival (p--.044). Conclusion The low levels of IGFPB7 in HGSC relative to normal tissues, and association with survival are consistent with a purported role in tumour suppressor pathways.